A hallmark of the Myeloma Institute for Research and Therapy (MIRT) is a program of clinical trials that challenge the traditional body of thought on disease treatment in order to improve outcomes. The physicians at MIRT work in tandem with myeloma scientists to bring the ‘bench of research to the bedside of the patient’ and back again to optimize diagnosis and treatments.
The “Total Therapy” approach to the treatment of multiple myeloma, with its focus on attacking myeloma from all fronts, has been at the core of successful outcomes at MIRT. Starting with Total Therapy 1 in 1989, outcomes have continued to improve through the incorporation of new agents and adjustments in pre-transplant consolidation and post-transplant maintenance phases of care.
MIRT partners with the SouthWest Oncology Group (SWOG) on collaborative, multi-center clinical trials, and enrolls more patients on myeloma SWOG trials than any other facility. MIRT also participates in pharmaceutical industry trials in order to give patients access to some of the latest pharmaceutical advances.
To learn more about clinical trials,
please visit the National Cancer Institute by clicking here.
Clinical trials open to enrollment at MIRT are organized under the following headings. Some trials are listed under multiple headings.
Total Therapy 4 (UARK 2008-01)
Total Therapy 4: A Phase III Trial for Low Risk Myeloma: A Randomized Trial Comparing Standard Total Therapy 3 (S-TT3) With TT3-Lite (L-TT3)
Total Therapy 5 (UARK 2008-02)
Total Therapy 5: A Phase II Trial for High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by applying Non-Host-Exhausting and Timely Dose-Reduced MEL-80+VRD-PACE Tandem Transplants with Interspersed MEL-20-VTD-PACE and alternating V-RD AND M-RD Maintenance
Immunotherapy/Chemotherapy (UARK 2003-26) A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DT PACE Chemotherapy and Autologous Transplant in Multiple Myeloma
Myeloma and Amyloidosis (SWOG 0115) A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) and Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) for High Risk Patients with Multiple Myeloma and/or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study)
Untreated Myeloma without Intent for Autologous Transplant (SWOG 0777)
A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induciton, in Patients with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant
Total Therapy 6 (UARK 2008-03)
A Phase II trial for previously treated patients, regardless of previous therapy.
Immunotherapy/Chemotherapy (UARK 2003-26) A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DT PACE Chemotherapy and Autologous Transplant in Multiple Myeloma
Natural Killer Cells (UARK 2003-18)
A Phase II Study of KIR-ligand Mismatched Natural Killer Cells Transfused before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma
Natural Killer Cells (UARK 2003-18)
A Phase II Study of KIR-ligand Mismatched Natural Killer Cells Transfused before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma
Myeloma and Amyloidosis (SWOG 0115)
A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) and Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) for High Risk Patients with Multiple Myeloma and/or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study)
Chimeric Antibody Against Interleukin-6 (UARK 2004-23)
A Phase I Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects with B-cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease
Myeloma and Amyloidosis (SWOG 0115)
A Phase II trial evaluating modified high dose melphalan (100mg/m2) and autologous peripheral blood stem cell supported transplantation for patients with AL amyloidosis or patients with multiple myeloma who are older than 70 years old or have poor renal function.
Myeloma and Amyloidosis (SWOG 0115)
A Phase II trial evaluating modified high dose melphalan (100mg/m2) and autologous peripheral blood stem cell supported transplantation for patients with AL amyloidosis or patients with multiple myeloma who are older than 70 years old or have poor renal function.
Chimeric Antibody Against Interleukin-6 (UARK 2004-23)
A Phase I study of multiple intravenous administrations of a chimeric antibody against Interleukin-6 (CNTO 328) in subjects with B-cell non-Hodgkin’s lymphoma, multiple myeloma, or Castleman’s disease.
Immunotherapy/Chemotherapy (UARK 2003-26)
A pilot study of MAGE-A3 and NY-ESO-1 immunotherapy in combination with DT-PACE chemotherapy and autologous transplant in multiple myeloma.
Natural Killer Cells (UARK 2003-18)
A Phase II study of KIR-ligand natural killer cells transfused before autologous stem cell transplant in relapsed multiple myeloma.
Treatment of Proven or Probable Invasive Aspergillosis (UARK 2008-11)
The purpose of this trial is to compare the efficacy of anidulafungin and voriconazole in combination to that of voriconazole alone when used for primary therapy.
